Skip to content
OpenCapital
Get started

Organon OGN Number of shareholder derivative lawsuits filed

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept ogn:NumberOfShareholderDerivativeLawsuitsFiled.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Organon's number of shareholder derivative lawsuits filed?
Organon (OGN) reported number of shareholder derivative lawsuits filed of 2 in Q3 2025.